BioCryst Pharmaceuticals (NASDAQ:BCRX) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $8.56 and traded as high as $9.48. BioCryst Pharmaceuticals shares last traded at $9.38, with a volume of 1,635,305 shares.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BCRX. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. Cantor Fitzgerald boosted their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th. Wall Street Zen cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Needham & Company LLC cut their price objective on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Finally, Citizens Jmp increased their target price on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, May 7th. Eight analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $20.80.

BioCryst Pharmaceuticals Stock Down 1.4%

The firm’s 50 day simple moving average is $9.21 and its two-hundred day simple moving average is $8.56. The stock has a market cap of $2.38 billion, a P/E ratio of -5.27 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The business had revenue of $156.41 million for the quarter, compared to analyst estimates of $151.12 million. During the same period last year, the company posted $0.20 earnings per share. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. As a group, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.58 EPS for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Larson Financial Group LLC boosted its stake in BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 3,267 shares during the period. Focus Partners Wealth acquired a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter worth approximately $77,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of BioCryst Pharmaceuticals by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares during the period. Envestnet Portfolio Solutions Inc. bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth approximately $81,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter worth approximately $81,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.